The Intelligence from The Economist
Forever young: the business of longevity drugs
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
The success of GLP-1s has prompted biotechs to approach the challenge differently. After years of false starts and disappointing results, longevity drugs could be on the horizon. Do immigrants from some countries commit more sex crimes? And the big business of miniatures.
Guests and host:
- Shailesh Chitnis, global business writer
- James Fransham, data correspondent
- Sascha Lowdermilk, culture intern
- Ọrẹ Ogunbiyi, co-host of “The Intelligence”
Topics covered:
- Longevity drugs, biotechnology, ageing
- Immigration, sex crime, Britain
- Miniatures, 3D printing, hobbies
Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
Hosted on Acast. See acast.com/privacy for more information.